150 related articles for article (PubMed ID: 21206384)
21. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
22. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
23. A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.
Hotta K; Kiura K; Tabata M; Takigawa N; Tanimoto M; Ueoka H
Chest; 2014 Dec; 146(6):e222-e225. PubMed ID: 25451370
[No Abstract] [Full Text] [Related]
24. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
25. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
26. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
27. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
Murakami S; Yokose T; Saito H; Sakuma Y; Matsukuma S; Hasegawa C; Kondo T; Oshita F; Ito H; Tsuboi M; Nakayama H; Kameda Y; Noda K; Yamada K
Lung Cancer; 2010 Sep; 69(3):361-4. PubMed ID: 20659620
[TBL] [Abstract][Full Text] [Related]
28. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
[TBL] [Abstract][Full Text] [Related]
29. Personalized oncology in interventional radiology.
Abi-Jaoudeh N; Duffy AG; Greten TF; Kohn EC; Clark TW; Wood BJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1083-92; quiz 1093. PubMed ID: 23885909
[TBL] [Abstract][Full Text] [Related]
30. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
31. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
[TBL] [Abstract][Full Text] [Related]
32. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma.
Hong M; Kim RN; Song JY; Choi SJ; Oh E; Lira ME; Mao M; Takeuchi K; Han J; Kim J; Choi YL
J Thorac Oncol; 2014 Mar; 9(3):419-22. PubMed ID: 24518094
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
34. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
35. Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Kalemkerian GP; Narula N; Kennedy EB
J Oncol Pract; 2018 May; 14(5):323-327. PubMed ID: 29589987
[No Abstract] [Full Text] [Related]
36. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline.
Rekhtman N; Leighl NB; Somerfield MR
J Oncol Pract; 2015 Mar; 11(2):135-6. PubMed ID: 25515718
[No Abstract] [Full Text] [Related]
37. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
[TBL] [Abstract][Full Text] [Related]
38. Targeted agents in the management of small cell lung cancer - present and future.
Srivastava R; Lebowicz Y; Jamil MO
Drugs Today (Barc); 2018 Aug; 54(8):479-488. PubMed ID: 30209442
[TBL] [Abstract][Full Text] [Related]
39. Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on supportive care issues related to lung cancer.
Boehmer L; Waqar S; Butler S; Sezhiyan A; Govindan R
J Thorac Oncol; 2011 Mar; 6(3):645-9. PubMed ID: 21270665
[TBL] [Abstract][Full Text] [Related]
40. American Society of Clinical Oncology--46th annual meeting.
Al-Shamahi A; Murch L; Kirkham K
IDrugs; 2010 Aug; 13(8):506-9. PubMed ID: 20721815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]